All AbMole products are for research use only, cannot be used for human consumption.
KB-R7943 is a plasma membrane Na(+)/Ca(2+) exchanger inhibitor. KB-R7943 reversibly inhibits inward and outward Na+/Ca2+ exchange in a dose-dependent manner (MCU; IC50 = 5.5 μM), but it does not affect Na+-dependent transport systems or ionotropic glutamate receptors. In addition, the effects of KB-R7943 on Ca(2+) homeostasis provide new evidence for the role of mitochondria modulating Ca(2+)-release and regenerative Ca(2+)-oscillations. KB-R7943 (10 and 30 microM) suppressed the tonotropic effect of ouabain, and prolonged the onset time of extra-systole induced by ouabain in isolated atria. KB-R7943 suppresses ouabain-induced arrhythmias through inhibition of the reverse-mode NCX. KB-R7943 is also a potent blocker of the transient receptor potential channels (TRPC) TRPC3, TRPC5 and TRPC6.
 |
Source | J Cardiol (2015). Figure 2. KB-R7943 |
| Method | incrementally | |
| Cell Lines | rabbits | |
| Concentrations | 0.5, 1.0 and 5.0 μM | |
| Incubation Time | ||
| Results | KB-R7943 inhibited the activity of the VPBs but did not prevent pace-induced VF |
| Cell Experiment | |
|---|---|
| Cell lines | neurons, astrocytes, and microglia |
| Preparation method | Na+-Ca2+ Exchange Activity. Na+-Ca2+ exchange activity was determined by assaying Na+-dependent Ca2+ uptake as reported previously (Takuma et al., 1994). Briefly, the cells were preincubated in Hanks' balanced saline solution (HBSS) for 20 min, and the medium was switched to HBSS containing Ca2+ and incubated for 5 min. To increase intracellular Na+ concentration, 1 mM ouabain plus 20 μM monensin (for astrocytes and microglia) and 10 μM monensin (for neurons) were used. Monensin was added simultaneously with the isotope. Ouabain was added 5 min before monensin in astrocytes and microglia. NCX inhibitors were added 5 min before monensin and present during Ca2+ uptake reaction. |
| Concentrations | 0~10 μ M |
| Incubation time | 5 min |
| Animal Experiment | |
|---|---|
| Animal models | cerebral cortex (A) and striatum (B) after MCA occlusion in rats |
| Formulation | 20% soybean oil |
| Dosages | 3 mg/kg |
| Administration | bolus i.v. |
| Molecular Weight | 427.49 |
| Formula | C16H17N3O3S.CH3SO3H |
| CAS Number | 182004-65-5 |
| Solubility (25°C) | DMSO 27 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Calcium Channel Products |
|---|
| CBD3063
CBD3063 is a selective, first-in-class, CRMP2-based peptidomimetic small molecule, which allosterically regulates Cav2.2 to achieve analgesia and pain relief without negative side effect profiles. |
| TTA-A8
TTA-A8 is a short-acting T-type calcium channel antagonist with oral activity, exhibiting an IC50 value of 31.3 nM in the FLIPR depolarization assay. |
| MONIRO-1
MONIRO-1 is a T-type and N-type calcium channel blocker with IC50 values of 34, 3.3, 1.7 and 7.2 µM against hCav2.2, hCav3.1, hCav3.2 and hCav3.3, respectively. |
| Azumolene
Azumolene (EU4093 free base), a Dantrolene analog, is a muscle relaxant. |
| Nexopamil
Nexopamil is a calcium antagonist of Ca2+ channel, 5HT2, 5HT1A, 5HT1C and dopamine D2 receptors. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
